Although Cimerli had captured the highest utilization in the ranibizumab category, its continued availability in the US seems precarious. A press release by Formycon AG, part owner of the biosimilar’s developer (Bioeq), stated last week that ”Due to the increasing price discounts among ranibizumab providers in the US, Bioeq AG, the exclusive license holder of … Continue reading Availability of Top Ranibizumab Biosimilar May be Paused